|
Volumn 104, Issue 1, 2012, Pages
|
Era of personalized medicine may Herald end of soaring cancer costs
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GEFITINIB;
IMATINIB;
TRASTUZUMAB;
CANCER SURVIVAL;
CANCER THERAPY;
COST CONTROL;
COST OF ILLNESS;
DRUG APPROVAL;
EUROPE;
FRANCE;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HUMAN;
MOLECULAR DIAGNOSIS;
NEOPLASM;
NOTE;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
CANCER CARE FACILITIES;
COST SAVINGS;
DRUG COSTS;
EUROPEAN UNION;
HEALTH CARE COSTS;
HUMANS;
INDIVIDUALIZED MEDICINE;
INTERDISCIPLINARY COMMUNICATION;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
QUALITY OF HEALTH CARE;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 84855490786
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr536 Document Type: Note |
Times cited : (7)
|
References (0)
|